66770 Federal Register / Vol. 75, No. 209 / Friday, October 29, 2010 / Notices 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at 

any Department of Energy facility who 

were exposed to radiation but for whom 

it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters To Be Discussed: The agenda 

for the Advisory Board meeting 

includes: NIOSH Program Update and 

Program Evaluation; Department of 

Labor (DOL) Program Update; 

Department of Energy (DOE) Program 

Update; Los Alamos National 

Laboratory Work Group Update; Board 

Session to Discuss Evaluating Exposure 

Potential for Radiological Materials in 

Minor Quantities or Uses; SEC petitions 

for: Linde Ceramics Plant (Tonawanda, 

New York), General Electric Company 

(Evendale, Ohio), Dow Chemical 

(Madison, Illinois), Simonds Saw and 

Steel Company (Lockport, New York), 

Hangar 481 of Kirkland Airforce Base 

(Albuquerque, New Mexico), BWX 

Technologies (Lynchburg, Virginia), and 

Texas City Chemicals Inc. (Texas City, 

Texas); SEC Petition Status Updates; 

SEC Class Definition Assessment 

Report; Subcommittee and Work Group 

Reports; and Board Work Sessions. 

The agenda is subject to change as 

priorities dictate. 

In the event an individual cannot 

attend, written comments may be 

submitted in accordance with the 

redaction policy provided below. Any 

written comments received will be 

provided at the meeting and should be 

submitted to the contact person below 

well in advance of the meeting. 

Policy on Redaction of Board Meeting 

Transcripts (Public Comment): (1) If a 

person making a comment gives his or 

her name, no attempt will be made to 

redact that name; (2) NIOSH will take 

reasonable steps to ensure that 

individuals making public comment are 

aware of the fact that their comments 

(including their name, if provided) will 

appear in a transcript of the meeting 

posted on a public Web site. Such 

reasonable steps include: (a) A 

statement read at the start of each public 

comment period stating that transcripts 

will be posted and names of speakers 

will not be redacted; (b) A printed copy 

of the statement mentioned in (a) above 

will be displayed on the table where 

individuals sign up to make public 

comments; (c) A statement such as 

outlined in (a) above will also appear 

with the agenda for a Board Meeting 

when it is posted on the NIOSH Web 

site; (d) A statement such as in (a) above 

will appear in the Federal Register 

Notice that announces Board and 

Subcommittee meetings; (3) If an 

individual in making a statement 

reveals personal information (e.g., 

medical information) about themselves 

that information will not usually be 

redacted. The NIOSH FOIA coordinator 

will, however, review such revelations 

in accordance with the Freedom of 

Information Act and the Federal 

Advisory Committee Act and if deemed 

appropriate, will redact such 

information; (4) All disclosures of 

information concerning third parties 

will be redacted; and (5) If it comes to 

the attention of the DFO that an 

individual wishes to share information 

with the Board but objects to doing so 

in a public forum, the DFO will work 

with that individual, in accordance with 

the Federal Advisory Committee Act, to 

find a way that the Board can hear such 

comments. 

Contact Person for More Information: 

Theodore Katz, M.P.A., Designated 

Federal Officer, NIOSH, CDC, 1600 

Clifton Road, NE., Mailstop E–20, 

Atlanta, Georgia 30333, telephone: (513) 

533–6800, toll free: 1 (800) CDC–INFO, 

e-mail: ocas@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

Notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: October 22, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–27455 Filed 10–28–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PA–07–030: 

Program Project: Membrane Fusion. 

Date: November 23, 2010. 

Time: 11 a.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Nitsa Rosenzweig, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1102, 

MSC 7760, Bethesda, MD 20892, (301) 435– 

1747. rosenzweign@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 21, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27325 Filed 10–28–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Clinical 

Proteomic Technologies for Cancer Initiative 

Research. 

Date: December 13–15, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Adriana Stoica, PhD, 

Scientific Review Officer, Special Review & 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES